Genitourinary Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 2.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Genitourinary Drugs Market Analysis
The genitourinary drugs market is expected to grow at a CAGR of 2.9% during the forecast period.
Initially, COVID-19 impacted the studied market owing to cancellations of elective procedures, including genitourinary tract infection treatments. Also, COVID-19 infection had been reported to worsen the symptoms of people with genitourinary disorders. For instance, according to an article published in the Asian Journal of Urology in July 2021, coronaviruses could cause urological symptoms when they infect the genitourinary system. COVID-19 was responsible for genitourinary organ dysfunction and damage. Patients with COVID-19 were found to have kidney impairment in several studies. Some research studies indicated that COVID-19 infection poses the greatest threat to the respiratory, digestive, and reproductive systems. Therefore, the genitourinary market was significantly impacted by COVID-19 in its initial phase. However, post-pandemic, the market started to recover since the restrictions were lifted and elective procedures resumed worldwide. The market is expected to gain pace during the forecast period owing to rising research and development activities for innovation in genitourinary drugs.
The high burden of genitourinary disorders is expected to create opportunities for market players' product innovation and launches which is expected to propel market growth. For instance, as per the report published by the World Health Organization in November 2021, more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic. Sexually transmitted infections (STIs) are associated with genitourinary complications which are projected to propel the demand for developing a genitourinary drug for the effective treatment of such diseases, thereby fueling the growth of the market.
Furthermore, the high prevalence of urinary tract infections and urinary incontinence is also contributing to the market growth. For instance, according to a Statpearls article updated in August 2022, it is estimated that around 423 million people (20 years and older) worldwide experience some form of urinary incontinence. The high burden of urinary incontinence globally is expected to propel the market growth.
Additionally, increasing investments in research and developments (R&D) activities for developing novel molecules for treating genitourinary diseases, and an increasing number of pipeline drugs are expected to drive the market during the forecast period. For instance, in February 2022, Asieris Pharmaceuticals received the clinical trial application (CTA) approval for Hexvix, a drug for the diagnosis of bladder cancer, from the National Medical Products Administration (NMPA) of China.
However, increasing counterfeit drugs and a lack of awareness about infections and treatment medications are expected to restrain the genitourinary drug market.
Genitourinary Drugs Market Trends
This section covers the major market trends shaping the Genitourinary Drugs Market according to our research experts:
Genital Herpes is Expected to Hold a Significant Market Share Over the Forecast Period
Genital herpes is a sexually transmitted infection that can cause blisters and open sores (lesions) in the genital area but can also be asymptomatic. Herpes simplex virus II is the cause of most cases of genital herpes.
According to a WHO March 2022 update, an estimated 491 million people worldwide aged 15 to 49 (13%) have herpes simplex virus (HSV)-2 infection annually. According to the same source, an estimated 3.7 billion people under 50 (67%) have HSV-1 infection globally. Also, according to a CDC 2021 update, there were an estimated 572 thousand new genital herpes infections in the United States in a single year in 2021. HSV-2 infection is more common among women than among men. The high burden of this disease is expected to propel the drug demand to meet the unmet treatment requirements, which are expected to expedite the segment's growth during the forecast period.
The strategic initiatives adopted by market players for the development of advanced genital herpes drugs are expected to boost the segment's growth. For instance, in July 2021, AiCuris Anti-infective Cures AG initiated Phase III development that will assess orally administered pritelivir for the treatment of drug-resistant mucocutaneous herpes simplex virus (HSV) infections in the immunocompromised. The rising clinical trials are expected to boost segment growth during the forecast period.
Moreover, the high R&D investments by the government and private entities in the STIs are further expected to have a significant impact on the market. For instance, as per the National Center for Health Statistics (NCHS), the investment for sexually transmitted infection research in the United States in 2021 was USD 404 million. More research is expected to spur the launch of new products in the segment propelling the market growth.
North America is Expected to Hold a Significant Market Share Over The Forecast Period
North America is expected to hold a significant share of the genitourinary drugs market due to the high prevalence of genitourinary diseases, greater awareness, and the presence of robust healthcare infrastructure in the region.
According to an article published in the Canadian Journal of Kidney Health and Disease in April 2022, glomerulonephritis (GN) is a major cause of kidney failure and accounts for 20% of incident cases of end-stage kidney disease (ESKD) in Canada annually.
Furthermore, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021, in the United States, approximately 30 million men had erectile dysfunction (ED). Additionally, a research study published in Canadian Urology Association Journal in October 2021 stated that erectile dysfunction is highly prevalent in Canada. The study also reported that approximately 40% of men in their 40s experienced ED of varying degrees of severity, and the prevalence of ED increases by about 10% per decade. Thus, the region's high burden of genitourinary diseases will increase the demand for drugs to treat such conditions, thereby boosting market growth.
Additionally, the research and development of novel antibiotics for urinary tract infections are expected to aid in market growth. For instance, in April 2022, the FDA approved the supplemental New Drug Applications (sNDAs) for Zerbaxa (ceftolozane and tazobactam) to include the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis, in pediatric patients (birth to less than 18 years old). Thus, the approvals for various drugs used to treat genitourinary conditions in different age groups are expected to boost the market in the region over the forecast period.
Genitourinary Drugs Industry Overview
The genitourinary drugs market is moderately competitive in nature. Major market players are investing high capital in R&D and adopting many strategies, such as new product launches and developments, geographical expansions, collaborations, and acquisitions, to strengthen their market position in the global genitourinary drugs market. Some key market players include Merck and Co. Inc., Cipla Inc., Pfizer, Allergen, and Melinta Therapeutics Inc, among others.
Genitourinary Drugs Market Leaders
-
Melinta Therapeutics Inc.
-
Merck & Co. Inc.
-
Pfizer Inc.
-
GlaxoSmithKline
-
Cipla Inc.
*Disclaimer: Major Players sorted in no particular order
Genitourinary Drugs Market News
- In November 2022, GSK PLC reported that a new drug, called gepotidacin, was effective in two large clinical trials involving approximately 3,000 patients for treating urinary tract infections.
- In February 2022, Veru presented the updated data from the phase 1b/2 Sabizabulin study in men with metastatic castration-resistant prostate cancer at the 2022 ASCO genitourinary cancers symposium.
Genitourinary Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Genitourinary Disorders
- 4.2.2 Increasing Number of Pipeline Products
-
4.3 Market Restraints
- 4.3.1 Lack of Therapy Compliance
- 4.3.2 Increasing Advent of Counterfeit Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Disease Type
- 5.1.1 Erectile dysfunction
- 5.1.2 Gonorrhoea
- 5.1.3 Genital Herpes
- 5.1.4 Urinary Tract Infections
- 5.1.5 Urinary Incontinence
- 5.1.6 Glomerulonephritis
- 5.1.7 Chronic renal failure
- 5.1.8 Other Disease Types
-
5.2 By Drug Type
- 5.2.1 Hormonal Therapy
- 5.2.2 Impotence Agents
- 5.2.3 Uterine Relaxants
- 5.2.4 Urinary Antispasmodics
- 5.2.5 Urinary pH Modifiers
- 5.2.6 Uterine Stimulants
- 5.2.7 Miscellaneous Genitourinary Tract Agents
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Eli Lilly and Company
- 6.1.2 GlaxoSmithKline PLC
- 6.1.3 Cipla Inc.
- 6.1.4 Melinta Therapeutics Inc.
- 6.1.5 Merck & Co. Inc.
- 6.1.6 Novartis AG
- 6.1.7 Pfizer Inc.
- 6.1.8 Bayer AG
- 6.1.9 F. Hoffmann-La Roche Ltd
- 6.1.10 Camber Pharmaceuticals, Inc.
- 6.1.11 Viatris Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Genitourinary Drugs Industry Segmentation
As per the scope of the report, genitourinary drugs are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. Patients suffering from diseases and infections related to genitourinary systems have been depending on steroids and immunosuppressants, which are chemically synthesized and may reciprocate with severe side effects such as insomnia, acne, nausea, vomiting, and diarrhea.
The Genitourinary Drugs Market is Segmented by Disease Type (Erectile dysfunction, Gonorrhoea, Genital Herpes, Urinary Tract Infections, Urinary Incontinence, Glomerulonephritis, Chronic renal failure, Other Disease Types), Drug Type (Hormonal Therapy, Impotence Agents, Uterine Relaxants, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Stimulants, Miscellaneous Genitourinary Tract Agents), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Disease Type | Erectile dysfunction | |
| Gonorrhoea | ||
| Genital Herpes | ||
| Urinary Tract Infections | ||
| Urinary Incontinence | ||
| Glomerulonephritis | ||
| Chronic renal failure | ||
| Other Disease Types | ||
| By Drug Type | Hormonal Therapy | |
| Impotence Agents | ||
| Uterine Relaxants | ||
| Urinary Antispasmodics | ||
| Urinary pH Modifiers | ||
| Uterine Stimulants | ||
| Miscellaneous Genitourinary Tract Agents | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Genitourinary Drugs Market Research FAQs
What is the current Global Genitourinary Drugs Market size?
The Global Genitourinary Drugs Market is projected to register a CAGR of 2.9% during the forecast period (2024-2029)
Who are the key players in Global Genitourinary Drugs Market?
Melinta Therapeutics Inc., Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline and Cipla Inc. are the major companies operating in the Global Genitourinary Drugs Market.
Which is the fastest growing region in Global Genitourinary Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Genitourinary Drugs Market?
In 2024, the North America accounts for the largest market share in Global Genitourinary Drugs Market.
What years does this Global Genitourinary Drugs Market cover?
The report covers the Global Genitourinary Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Genitourinary Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Genitourinary Drugs Industry Report
Statistics for the 2024 Genitourinary Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Genitourinary Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
